TRVI Stock Analysis: Trevi Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.265m USD | 12M Return: 90.6% | US89532M1018 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 24.3M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic cough, specifically targeting patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The companys lead investigational product, Haduvio, is an oral extended-release formulation of nalbuphine, currently undergoing a Phase 2b clinical trial for chronic cough in IPF patients and a Phase 2a trial for refractory chronic cough.
The company operates in the Health Care sector (Pharmaceuticals sub-industry) under the GICS classification. As a clinical-stage biopharmaceutical firm, Trevi has no approved commercial products and is dependent on capital markets, licensing agreements, and eventual commercialization to generate revenue. Trevi holds a license agreement with Keenova Therapeutics plc covering nalbuphine hydrochloride formulations, and was incorporated in 2011, headquartered in New Haven, Connecticut. The company trades on NASDAQ under the ticker TRVI.
- Haduvio Phase 2b IPF chronic cough trial data readout
- FDA regulatory progress for Haduvio chronic cough indication
- Cash runway extends through key Haduvio trial milestones
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.12 > 0.02 and ΔFCF/TA 8.57 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.16 > 3% & CFO -52.6m > Net Income -51.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 37.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (156.6m) vs 12m ago 20.14% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.07%; Δ -0.07% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.96 (Total Current Assets 325.7m - Total Current Liabilities 8.74m) / Total Assets 330.5m |
| B: -1.09 (Retained Earnings -360.8m / Total Assets 330.5m) |
| C: -0.22 (EBIT TTM -59.6m / Avg Total Assets 269.4m) |
| D: 35.68 (Book Value of Equity 321.5m / Total Liabilities 9.01m) |
| Altman-Z'' = 38.71 = AAA |
As of September 18, 2026, the stock is trading at USD 15.21 with a total of 1,500,738 shares traded. Over the past week, the price has changed by -4.40%, over one month by -17.69%, over three months by -7.09% and over the past year by +90.60%.
Current recommended Stop Loss: 13.90 (which is 8.6% or 1.7 ATR below the current price).
Trevi Therapeutics has received a consensus analysts rating of 4.88. Therefore, it is recommended to buy TRVI.
- StrongBuy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 28.2 | 85.3% |
P/B = 7.0417
Revenue TTM = 0.0 USD
EBIT TTM = -59.6m USD
EBITDA TTM = -59.4m USD
Long Term Debt = 276k USD (estimated: total debt 605k - short term 329k)
Short Term Debt = 329k USD (from shortTermDebt, last quarter)
Debt = 605k USD (from shortLongTermDebtTotal, last quarter) (leases 605k already included)
Net Debt = -318.3m USD (calculated: Debt 605k - CCE 318.9m)
Enterprise Value = 1.95b USD (2.27b + Debt 605k - CCE 318.9m)
Interest Coverage Ratio = unknown (Ebit TTM -59.6m / Interest Expense TTM 0.0)
EV/FCF = -49.43x (Enterprise Value 1.95b / FCF TTM -39.4m)
FCF Yield = -2.02% (FCF TTM -39.4m / Enterprise Value 1.95b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 132k) / Revenue TTM)
Tobins Q-Ratio = 5.89 (Enterprise Value 1.95b / Total Assets 330.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 605k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -47.1m (EBIT -59.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 37.28 (Total Current Assets 325.7m / Total Current Liabilities 8.74m)
Debt / Equity = 0.00 (Debt 605k / totalStockholderEquity, last quarter 321.5m)
Debt / EBITDA = 5.36 (negative EBITDA) (Net Debt -318.3m / EBITDA -59.4m)
Debt / FCF = 8.08 (negative FCF - burning cash) (Net Debt -318.3m / FCF TTM -39.4m)
Total Stockholder Equity = 216.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -18.97% (Net Income -51.1m / Total Assets 330.5m)
RoE = -23.59% (Net Income TTM -51.1m / Total Stockholder Equity 216.7m)
RoCE = -27.45% (EBIT -59.6m / Capital Employed (Equity 216.7m + L.T.Debt 276k))
RoIC = -14.61% (negative operating profit) (NOPAT -47.1m / Invested Capital 322.1m)
WACC = 5.25% (E(2.27b)/V(2.27b) * Re(5.25%) + D(605k)/V(2.27b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 5.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.79 | Cagr: 22.32%
[DCF] Fair Price = unknown (Cash Flow -39.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.13 | Chg30d=-3.18% | Revisions=-25% | Analysts=10
EPS current Year (2026-12-31): EPS=-0.48 | Chg30d=-2.15% | Revisions=-55% | GrowthEPS=-49.7% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.58 | Chg30d=-3.44% | Revisions=-44% | GrowthEPS=-20.5% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -61% (up=2, down=13)